Autobahn Therapeutics, Inc. announced that it has raised $32.7 million in a round of funding on September 8, 2022. The Transaction included participation from GT Healthcare Capital Partners, returning investors Arch Venture Partners, L.P., The Invus Group, LLC, Bristol-Myers Squibb Company,Biogen Inc., BVF Partners L.P., Pfizer Venture Investments LLC, Alexandria Venture Investments, LLC, Section 32, LLC, Samsara BioCapital LLC and CHI Advisors LLC.